OssDsign: FDA expansion for Catalyst is huge - Redeye

Redeye is enthusiastic by today’s news of the FDA expanding the approval for Catalyst to interbody cages in spinal fusion. The approval enables full on-label usage in spinal surgery and positions OssDsign as one of only three companies with such an approval. Naturally, the company’s value proposition is significantly increased, and its commercialisation should see a tailwind as we advance. We reiterate our SEK13 base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/942898/ossdsign-fda-expansion-for-catalyst-is-huge?utm_source=finwire&utm_medium=RSS